The ITP World Impact Survey (I-WISh) is a collaborative investigation among global ITP experts, patient support groups and Novartis Pharmaceuticals Corporation.
The purpose of this cross-sectional global survey is to analyze and report the real-world impact of immune thrombocytopenia (ITP) on patients’ quality of life, management of the condition, and opinions toward treatment. I-WISh is the largest observational global survey ever conducted in ITP including 1,400 ITP patients and 480 health care providers who treat the condition from the following 14 countries: Canada, China, Colombia, Egypt, France, Germany, Italy, India, Japan, Norway, Spain, Turkey, United Kingdom, and United States.
Dr Drew Provan shares shares the various insights and key learned from the initial survey.
